Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Bibliographic Details
Title: Expert consensus statement on therapeutic drug monitoring and individualization of linezolid
Authors: Bin Lin, Yangmin Hu, Ping Xu, Tao Xu, Chunyan Chen, Le He, Mi Zhou, Zhangzhang Chen, Chunhong Zhang, Xuben Yu, Luo Fang, Junfeng Zhu, Yanlan Ji, Qun Lin, Hengbin Cao, Youqin Dai, Xiaoyan Lu, Changcheng Shi, Li Li, Changjiang Wang, Xumei Li, Qiongyan Fang, Jing Miao, Zhengyi Zhu, Guangyong Lin, Haichao Zhan, Shiwen Lv, Yalan Zhu, Xinjun Cai, Yin Ying, Meng Chen, Qiong Xu, Yiwen Zhang, Yubin Xu, Pea Federico, Saiping Jiang, Haibin Dai
Source: Frontiers in Public Health, Vol 10 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Public aspects of medicine
Subject Terms: linezolid, therapeutic drug monitoring, individualization, expert consensus, pharmacotherapy, Public aspects of medicine, RA1-1270
More Details: Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2296-2565
Relation: https://www.frontiersin.org/articles/10.3389/fpubh.2022.967311/full; https://doaj.org/toc/2296-2565
DOI: 10.3389/fpubh.2022.967311
Access URL: https://doaj.org/article/8f27801b335e446b964c24cd044db063
Accession Number: edsdoj.8f27801b335e446b964c24cd044db063
Database: Directory of Open Access Journals
More Details
ISSN:22962565
DOI:10.3389/fpubh.2022.967311
Published in:Frontiers in Public Health
Language:English